PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0231
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-06-22
First Named Inventor Stefa		n L. BURTSCHER
Art Unit		
Examiner Name		
Attorney Docket Number		16785.3

					U.S.	PATENTS			Remove		
Examiner Cite No Patent N		Patent Number	Kind Code <sup>1</sup>			entee or Applicant Releva		s,Columns,Lines where ant Passages or Relevant es Appear			
	1										
If you wisl	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicated Document		Relev		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publi						d butto			
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	taminer Cite No Number³ Country Code² i		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	+4		
	1	10010564	DE		C1	2001-07-05	Kollegger, Johann				
	2	95/29308	wo		A1	1995-11-02	Eidgenossische Materialprufungsur al.	nd, et			
	3	0197912	EP		A2	1986-02-13	Vorspann-Technik Gesellschaft m.b.H				

# | Application Number | Fing Date | 2006.06.22 | Finst Number | STATEMENT BY APPLICANT | (Not for submission under 37 CFR 1.99) | Examiner Name | Examiner Name | Attorney Docket Number | 16785.3 |

Α1

EP

1999-10-13

Bilginer + Berger

Date Considered

	5	2515423	DE	A1	1975-11-13	Fabrik, et al.					
	6	0554161	EP	A1	1993-01-26	Sondages Injections Forages, et al.					
	7	6601081	DE		1969-04-03	Rehm G					
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examine Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), itse of the article (when appropriate), itse of the item (book, magazine, pourmal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and office country where published.										
	1										

<sup>1</sup> See Kind Codes of USPTO Patient Documents at www.<u>USPTO.GDV</u> or MPEP 901.04. <sup>2</sup> Enter office that resued the document, by the two-letter code (WIPO Standard 513.) <sup>3</sup> Fee Impacts patient forcements, the notice of the patient forcement property from the force of the region of the Empart must preced the serial number of the patient document. The patient forcement for the patient forcement forcement for the patient forcement forcement forcement for the patient forcement forcement forcement forcement forcement forcement for the patient forcement for the patient forcement forcement for the patient forcement for

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature

4 0949389

# Application Number Filing Date 2006-05-22 Filing Date 2006-05-22 First Number Individual Proceedings of the Proceed Number Individual Procedure Number Individual Proceedings of the Pro

### CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tent of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(d)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

om of the signature.								
Signature	/R. Burns Israelsen/	Date (YYYY-MM-DD)	2006-06-22					
Name/Print	R. Burns Israelsen	Registration Number	42685					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolffice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sicklosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via filed in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.